These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25137170)

  • 61. [SIADH - a "shambles"].
    Ring T
    Ugeskr Laeger; 2012 Apr; 174(15):1041; author reply 1041. PubMed ID: 22590730
    [No Abstract]   [Full Text] [Related]  

  • 62. [Treatment of hyponatremia: new developments and controversies].
    Hensen J
    Dtsch Med Wochenschr; 2011 Apr; 136(17):904-9. PubMed ID: 21523644
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The syndrome of inappropriate antidiuretic hormone: current and future management options.
    Sherlock M; Thompson CJ
    Eur J Endocrinol; 2010 Jun; 162 Suppl 1():S13-8. PubMed ID: 20164215
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of hyponatremia induced by the syndrome of Inappropriate antidiuretic hormone secretion: a multidisciplinary spanish algorithm.
    Runkle I; Villabona C; Navarro A; Pose A; Formiga F; Tejedor A; Poch E
    Nefrologia; 2014; 34(4):439-50. PubMed ID: 25036057
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion.
    Gargani L; Schmidt PH; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1505-13. PubMed ID: 22103869
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
    Shoaf SE; Bricmont P; Dandurand A
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease.
    Imamura T
    Int Heart J; 2014; 55(6):482-3. PubMed ID: 25318555
    [No Abstract]   [Full Text] [Related]  

  • 71. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 72. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
    Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of single-dose of tolvaptan in neurocritical patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion.
    Llompart-Pou JA; Pérez-Bárcena J; Novo M; Raurich JM
    Med Intensiva; 2017 Nov; 41(8):501-503. PubMed ID: 28087091
    [No Abstract]   [Full Text] [Related]  

  • 74. [From hyponatremia to tolvaptan].
    Cernaro V; Santoro D; Lacquaniti A; Montalto G; Buemi M
    G Ital Nefrol; 2014; 31(1):. PubMed ID: 24671837
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients.
    Coussement J; Danguy C; Zouaoui-Boudjeltia K; Defrance P; Bankir L; Biston P; Piagnerelli M
    Am J Nephrol; 2012; 35(3):265-70. PubMed ID: 22378162
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Severe hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone].
    Foppiani L; Raggi F; Tagliabue M; Benso A; Brandolin I; Lo Pinto G
    Recenti Prog Med; 2013 Mar; 104(3):112-5. PubMed ID: 23548955
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
    Tanaka A; Nakamura T; Sato E; Node K
    Int J Cardiol; 2016 May; 210():1-3. PubMed ID: 26921537
    [No Abstract]   [Full Text] [Related]  

  • 78. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease.
    Kawada T
    Clin Exp Nephrol; 2016 Feb; 20(1):147-8. PubMed ID: 26070257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.